secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001104659-23-001980
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma highlights YUPELRI growth, $250M buyback progress, and ampreloxetine Phase 3 start
--------------------------------------------------------------------------------

- YUPELRI achieved all-time high net sales and profit in Q2 and Q3 2022; expects continued Q4 growth.
- $250M capital return program ~50% completed as of 12/31/2022; ~$95M GSK buyback and ~$33M open market repurchases.
- Ampreloxetine Phase 3 CYPRESS trial in MSA patients with nOH to start Q1 2023; orphan drug submission planned.
- Targeting Non-GAAP profitability by 2H 2023; $50M milestone if TRELEGY sales reach ~$2.86B in 2023.
- Sale of TRELEGY royalty interests for $1.1B upfront eliminated all debt; financial restructuring completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923001980/0001104659-23-001980-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923001980/tm232391d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-001980

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer